We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+8.51%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$7.52B
AUM Growth
+$1.2B
(+19%)
Cap. Flow
+$726M
Cap. Flow
% of AUM
9.65%
Top 10 Holdings %
Top 10 Hldgs %
19.11%
Holding
866
New
79
Increased
318
Reduced
279
Closed
56
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$75M |
| 2 |
Biogen
BIIB
|
+$70.7M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$60.1M |
| 4 |
Merck
MRK
|
+$54.6M |
| 5 |
Gilead Sciences
GILD
|
+$33.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$19.1M |
| 2 |
IRBT
iRobot
IRBT
|
+$15.5M |
| 3 |
Quest Diagnostics
DGX
|
+$15.4M |
| 4 |
Colgate-Palmolive
CL
|
+$14.8M |
| 5 |
Philip Morris
PM
|
+$12.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.26% |
| 2 | Technology | 16.05% |
| 3 | Financials | 11.26% |
| 4 | Consumer Discretionary | 7.98% |
| 5 | Communication Services | 7.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GBT
276
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $6.23M | 0.08% |
164,000
+73,000
| +80% | +$3.23M |
|
277
American Tower
AMT
$77.9B
| $6.19M | 0.08% |
42,596
-10,004
| -19% | -$1.47M |
|
278
McKesson
MCK
$100B
| $6.01M | 0.08% |
45,284
+29,745
| +191% | +$3.88M |
|
279
Martin Marietta Materials
MLM
$34.2B
| $5.97M | 0.08% |
32,790
-4,393
| -12% | -$907K |
|
280
Raymond James Financial
RJF
$33.1B
| $5.94M | 0.08% |
96,866
+48,086
| +99% | +$2.96M |
|
|
PX
281
DELISTED
Praxair Inc
PX
| $5.93M | 0.08% |
36,880
+8,029
| +28% | +$1.29M |
|
|
MRO
282
DELISTED
Marathon Oil Corporation
MRO
| $5.92M | 0.08% |
254,404
+192,093
| +308% | +$4.02M |
|
283
DXC Technology
DXC
$1.69B
| $5.91M | 0.08% |
63,151
-84,268
| -57% | -$7.46M |
|
284
Scotiabank
BNS
$106B
| $5.88M | 0.08% |
98,681
+15,129
| +18% | +$884K |
|
285
Ulta Beauty
ULTA
$20.6B
| $5.8M | 0.08% |
20,568
+16,744
| +438% | +$4.27M |
|
286
Larimar Therapeutics
LRMR
$400M
| $5.8M | 0.08% |
41,333
+27,583
| +201% | +$3.35M |
|
287
Prologis
PLD
$136B
| $5.78M | 0.08% |
85,284
+6,339
| +8% | +$417K |
|
|
FLIR
288
DELISTED
FLIR Systems, Inc. (DE) Common Stock
FLIR
| $5.77M | 0.08% |
+93,864
| New | +$5.53M |
|
289
AES
AES
$10.6B
| $5.7M | 0.08% |
406,894
+145,268
| +56% | +$1.96M |
|
290
Suncor Energy
SU
$75.9B
| $5.69M | 0.08% |
147,095
-1,366
| -0.9% | -$55.3K |
|
|
PNK
291
DELISTED
Pinnacle Entertainment Inc.
PNK
| $5.67M | 0.08% |
+168,447
| New | +$5.69M |
|
292
Canadian National Railway
CNI
$78B
| $5.61M | 0.07% |
62,533
-2,218
| -3% | -$194K |
|
293
Ball Corp
BALL
$17.2B
| $5.58M | 0.07% |
126,861
-71,854
| -36% | -$2.92M |
|
294
Mondelez International
MDLZ
$77.8B
| $5.48M | 0.07% |
127,492
+15,309
| +14% | +$653K |
|
295
Lexicon Pharmaceuticals
LXRX
$1.03B
| $5.43M | 0.07% |
509,000
+137,000
| +37% | +$1.57M |
|
296
American Airlines Group
AAL
$9.71B
| $5.43M | 0.07% |
131,370
-233,270
| -64% | -$9.12M |
|
|
RDUS
297
DELISTED
Radius Health, Inc.
RDUS
| $5.41M | 0.07% |
304,025
+23,500
| +8% | +$532K |
|
298
Kinder Morgan
KMI
$71.2B
| $5.41M | 0.07% |
305,210
-23,395
| -7% | -$418K |
|
|
ZGNX
299
DELISTED
Zogenix, Inc.
ZGNX
| $5.39M | 0.07% |
108,700
+28,700
| +36% | +$1.46M |
|
300
Consolidated Edison
ED
$41.3B
| $5.39M | 0.07% |
70,696
+42,312
| +149% | +$3.33M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q3 2018 Portfolio in Review
As of Q3 2018, Candriam SCA held 866 positions worth $7.52B, up 19% from $6.32B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Candriam SCA deployed $726M of net new capital in Q3 2018, opening 79 new positions and adding to 318 existing holdings. Its largest new stake was Varonis Systems: 541,092 shares worth $13.2M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 25% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Advanced Micro Devices, an estimated $19.1M trimmed.
- Candriam SCA's largest Q3 2018 buy was Varonis Systems: 541,092 shares worth $13.2M.
- Candriam SCA added most to Amgen in Q3 2018, an estimated $75M increase.
- Candriam SCA's biggest Q3 2018 reduction was Advanced Micro Devices, cutting an estimated $19.1M.
- Candriam SCA fully exited iRobot in Q3 2018, selling an estimated $15.5M.
- Candriam SCA's ten largest holdings make up 19% of its $7.52B portfolio in Q3 2018.
- Candriam SCA opened 79 new positions and closed 56 in Q3 2018.
- Candriam SCA's portfolio value rose 19% quarter-over-quarter to $7.52B.
Based on Candriam SCA's 13F filing for Q3 2018, filed 7 Nov 2018.